Actively Recruiting
Early Phase 1 Study of In Vivo CAR-T Drug Using LNP-mRNA Targeting CD19 in Adults With B-cell Malignancies
Led by Xinqiao Hospital of Chongqing · Updated on 2026-01-20
47
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying an mRNA therapeutic drug targeting CD19 for the treatment of malignant hematological tumors mainly derived from adult B cells, including acute lymphoblastic leukemia ALL and non-Hodgkin lymphoma NHL. Although existing treatments have improved survival rates, relapsed or refractory cases remain challenging. The study explores CD19, a key target in B-cell malignancies, using lipid nanoparticle LNP mRNA technology that has been developed and widely applied in areas such as COVID-19 vaccines and cancer therapies. The investigational treatment involves an in vivo CAR-T drug based on LNP-mRNA, which encapsulates mRNA encoding specific proteins related to anti-CD19 activity. This drug is delivered to the body intravenously or intramuscularly. The study is conducted as an early phase 1 trial, focusing on dose-limiting toxicity, maximum tolerated dose, and optimal biological dose assessments within specified timeframes after treatment. Participants aged 18 to 70 years with CD19-positive B-cell lymphoma or lymphocytic leukemia who have no standard treatment options will be involved. The study includes monitoring of dose safety, response rates, disease control, and progression-free survival over periods ranging from 1 month up to 2 years. Physical fitness and lesion assessments will be conducted, and participants will be closely followed for treatment effects and safety outcomes throughout the study duration.
CONDITIONS
Brief Title
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here